canada clinical guidance

Breast lump and nipple symptoms: recognition and referral

A Canadian clinical summary of breast lump and nipple symptoms: recognition and referral, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Ontario is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.

Ontario source: bounded use

Breast cancer pathway map supplies a Canadian implementation example for this summary. It must not be presented as the rule outside Ontario.
sources for this section:Ontario breast pathway

Source-attributed clinical priorities

  • Assess a new mass with breast and nodal examination and document skin, nipple and inflammatory features.
  • Use age- and presentation-appropriate diagnostic imaging and tissue assessment through the provincial breast pathway.
  • Refer rapidly for suspicious mass, pathologic nipple discharge, inflammatory change, skin tethering or concerning nodes.
  • Triple assessment integrates clinical examination, imaging and tissue diagnosis when a lesion is suspicious.
sources for this section:Ontario breast pathway

Practical assessment and management workflow

1
Document duration, cycle relation, pregnancy, lactation, family history, prior imaging and systemic symptoms.
2
Examine both breasts and regional nodes and note skin, nipple, fixation and inflammatory changes.
3
Order age- and presentation-appropriate diagnostic imaging through the provincial breast service.
4
Ensure imaging-pathology concordance and track the referral rather than reassuring from one component alone.
sources for this section:Ontario breast pathway

Safety, red flags and urgent escalation

  • Rapid inflammatory change, skin edema, ulceration or suspicious nodes requires expedited cancer assessment.
  • A persistent mass needs evaluation even when initial imaging is reported benign if findings are discordant.
  • Breast infection that does not improve as expected requires reassessment for abscess or malignancy.
sources for this section:Ontario breast pathway

Confirm the local pathway before acting

Ontario is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:Ontario breast pathway

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Ontario breast pathway

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Ontario Health (Cancer Care Ontario)Breast cancer pathway mapaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.